TD Cowen raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $99 from $59 and keeps a Buy rating on the shares. The firm updated its model following solid Q3 results driven by Tryngolza beat/raise. Cowen is adding $1.5B in peak global sales to theirmodel at $25k/yr.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Future Catalysts Support Buy Rating
- Ionis Pharmaceuticals price target raised to $95 from $80 at Barclays
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Ionis Pharmaceuticals Reports Strong Q3 2025 Growth
- Ionis Pharmaceuticals Shines in Q3 2025 Earnings Call